Sun Pharma completed its purchase of Nasdaq-listed Checkpoint Therapeutics by paying 355 million USD in upfront cash for each share at 4.10 USD. Checkpoint Therapeutics operates as a US-based immunotherapy and targeted oncology company. Sun Pharma made this announcement through a March 10 statement that served as a first step toward its goal of expanding its specialty pharma sector through Checkpoint Therapeutics acquisition.
Checkpoint Therapeutics is a commercial-stage company that is focused on the development of pioneering treatments for solid tumour cancers. The acquisition enables Sun Pharma to gain FDA-approved UNLOXCYT therapy which expands their offerings of cancer skin treatments. Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, emphasized the strategic importance of the deal, stating, “The acquisition further bolsters our innovative portfolio in onco-derm therapy.”
Sun Pharma has acquired Checkpoint in a deal that provides it with a 66% premium value using Checkpoint's share price from March 7, 2025 to strengthen its US market standing. James Oliviero, President and CEO of Checkpoint, highlighted the deal’s benefits, saying, “This transaction will maximize value for our stockholders and provide accelerated access to UNLOXCYT in the United States, Europe, and other markets worldwide.”
Sun Pharma adopts this purchase to support its plan for specialty pharmaceutical growth. The company focuses on oncology because the demand for innovative cancer treatments keeps increasing. Sun Pharma will advance toward global pharmaceutical leadership through the integration of Checkpoint’s knowledge base and research inventory.
Completion of the deal requires shareholder and regulatory approval for Checkpoint before it finishes during the second quarter of calendar year 2025. Sun Pharma continues its aggressive growth strategy by acquiring these assets which positions the company to benefit from expanding global demand for advanced cancer medical therapies.
